The pharmaceutical industry faces a structural realignment of its economic foundations. Between 2025 and 2030, a “super-cliff” of patent expirations […]
Kill the Patent Cliff: How to Turn a $400 Billion Revenue Loss into a Competitive Edge Read Post »
Introduction: Beyond the Courtroom — Why Patent Litigation is the Ultimate Pharma Value Driver Let’s be direct. If you’re an
The Litigator’s Lens: Turning Drug Patent Disputes into Your Definitive Investment Edge Read Post »
The pharmaceutical business model relies on a simple cycle. Companies invest billions into research, secure a period of market exclusivity
Win the Patent Cliff: How the 12-Year Biologic Advantage Reshapes the Drug Market Read Post »
The global pharmaceutical industry currently faces a historic loss-of-exclusivity super-cycle. Between 2025 and 2030, an estimated $200 billion to $400
The ‘Use It or Lose It’ Rule: Decoding 180-Day Generic Exclusivity Forfeiture Read Post »
The pharmaceutical supply chain is a system where the loss of exclusivity for a brand-name drug creates a massive transfer
Master the Patent Cliff for Better Pharmacy Margins Read Post »
The pharmaceutical industry is approaching a singularity. Between 2025 and 2030, a wave of patent expirations—often described as the “super-cliff”—will
Buy Low, Dispense High Read Post »
The foundational error in pharmaceutical valuation lies in conflating the statutory patent term with commercial exclusivity. Generalist investors and market
Forecast Pharma Revenue Without the Cliff Myth Read Post »
Big pharma used to treat loss of exclusivity as a weather event. You saw the date on the Gantt chart,
Steal Years Back From Your Patent Cliff Read Post »
The business model for off-patent medicine is undergoing a forced evolution. For four decades, the Hatch-Waxman Act provided a predictable
Secure the Future of Branded Generics Read Post »
Get fresh news and insights, drug patent expirations & more…
